Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
出版年份 2022 全文链接
标题
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
作者
关键词
-
出版物
MOLECULAR THERAPY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-09-09
DOI
10.1016/j.ymthe.2022.09.003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
- (2022) Robbie G. Majzner et al. NATURE
- CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
- (2022) Nikhil Hebbar et al. Nature Communications
- Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
- (2021) Evan W. Weber et al. SCIENCE
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
- (2021) Jing Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- Aberrant CD3-Positive, CD8-Low, CD7-Negative Lymphocytes May Appear During Viral Infections and Mimic Peripheral T-Cell Lymphoma
- (2020) Andreas Klameth et al. Diagnostics
- Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients
- (2020) Fuli Fan et al. INTERNATIONAL JOURNAL OF CANCER
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Naive T cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers
- (2019) Rajat K Das et al. Cancer Discovery
- Chimeric Antigen Receptors for T-Cell Malignancies
- (2019) Lauren D. Scherer et al. Frontiers in Oncology
- Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells
- (2019) Zinaida Good et al. NATURE BIOTECHNOLOGY
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
- (2019) Zhitao Gao et al. Journal of Genetics and Genomics
- An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
- (2018) Matthew L Cooper et al. LEUKEMIA
- CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
- (2018) Diogo Gomes-Silva et al. MOLECULAR THERAPY
- Overcoming Target Driven Fratricide for T Cell Therapy
- (2018) Eytan Breman et al. Frontiers in Immunology
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
- (2017) Paul M Maciocia et al. NATURE MEDICINE
- Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
- (2017) Diogo Gomes-Silva et al. Cell Reports
- Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
- (2017) Maksim Mamonkin et al. Cancer Immunology Research
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
- (2015) M. Mamonkin et al. BLOOD
- Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells
- (2015) K Pinz et al. LEUKEMIA
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- An Enigmatic Tail of CD28 Signaling
- (2010) J. S. Boomer et al. Cold Spring Harbor Perspectives in Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More